ATOME CEO on landmark Yara offtake deal & Villeta green fertiliser push

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce a major milestone for the company’s dermatology pipeline: the commencement of patient recruitment for its SKNJCT-004 Phase 2 clinical study, designed to non-invasively treat basal cell carcinoma of the skin. The trial has officially begun enrolling participants at the Cleveland Clinic Abu Dhabi, following earlier “study may proceed” approval granted by the UAE Department of Health. Bokhari explained that the study is expected to randomize 36 patients across four leading medical centers in the UAE. In addition to Cleveland Clinic Abu Dhabi, recruitment is set to begin at several other prominent institutions, including Sheikh Shakbout Medical City, Burjeel Medical City, Rashid Hospital, Clemenceau Medical Center, and the American Hospital of Dubai. This multi-center approach aims to accelerate enrollment while ensuring the study draws on a broad and diverse patient population. The SKNJCT-004 trial will assess the efficacy of two dose levels of Medicus Pharma’s investigational therapy D-MNA compared to a placebo control. Participants will be randomized in a 1:1:1 ratio into three groups: a placebo group receiving P-MNA, a low-dose group receiving 100μg of D-MNA, and a high-dose group receiving 200μg of D-MNA. The company believes that a non-invasive therapy could transform the standard of care for BCC by offering patients an alternative to surgery or other destructive modalities. Bokhari also highlighted that Medicus Pharma continues to advance its broader clinical program targeting BCC. The company’s SKNJCT-003 Phase 2 study is currently underway at nine clinical sites across the United States, with patient randomization having commenced in August 2024. In March 2025, the company reported a positively trending interim analysis from SKNJCT-003, demonstrating more than 60% clinical clearance—an encouraging early indicator of the therapy’s potential efficacy. The company has also closed its acquisition of Antev, a UK-based biotech focused on next-generation gonadotrophin releasing hormone antagonists, noting the company now controls three FDA-approved clinical studies. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #UAEHealth #NonInvasiveTherapy #Doxorubicin #ClinicalTrials #HealthcareInnovation

GoviEx Uranium Inc head of corporate communications Isabel Vilela talked with Proactive's Stephen Gunnion about the company’s recent developments, including progress in Niger and the planned transaction with Tombador Iron. Vilela explained that GoviEx had agreed with the Republic of Niger to extend the pause in arbitration over the Madaouela Project license for another six months. She noted, “The key point here is that both parties are willing to talk and negotiate, and we want to keep the dialogue going.” Vilela emphasised that the arbitration pause remains entirely separate from the company’s deal with Tombador Iron. She also provided an update on the reverse takeover transaction with Tombador, highlighting that over 40% of GoviEx security holders have already committed to supporting the deal. On the Tombador side, their shareholder vote is scheduled for early October, with GoviEx’s meeting planned later in the month. The company expects to close the transaction before the end of the year, pending regulatory approvals. Vilela outlined the benefits of the transaction, including access to Australian mining investors, an injection of between A$5 million and A$10 million at a premium to the current share price, and a tighter capital structure through share consolidation. Importantly, GoviEx shareholders will retain 75% of the combined company pre-raise. The business will also rebrand to Atomic Eagle, with a continued focus on developing the Muntanga Project. For more videos, visit Proactive’s YouTube channel. Don’t forget to give this video a like, subscribe to our channel, and enable notifications for future updates. #GoviExUranium #Uranium #MiningStocks #ASXListing #AtomicEagle #TombadorIron #MuntangaProject #Niger #UraniumMining #ProactiveInvestors

Genflow Biosciences PLC CEO Dr Eric Leire joined Proactive's Stephen Gunnion with news that the company has signed confidential disclosure agreements (CDAs) with two major animal health companies. Leire explained that these discussions are significant for shareholders as they broaden the company’s market potential, provide possible early cash inflows to reduce capital needs, and validate its scientific platform. “Our core science is focused on tackling ageing and muscle loss. The same approach we use for humans has real potential for companion animals,” Leire said. He noted that the global pet market is expanding, and Genflow’s work in this area could deliver solutions to extend lifespan and improve the quality of life for ageing dogs. He also highlighted that early safety data from the company’s first dog trials have been positive. The administration of the treatment was straightforward, with no signs of discomfort or behavioural change in the animals. Leire said this suggests the product could translate into a commercially viable therapy. The next key milestone will be efficacy data from the dog trials, expected within five months. Leire expressed confidence, citing strong results previously observed in mice studies. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to give the video a like, subscribe to the channel, and enable notifications for future content. #GenflowBiosciences #Biotech #Longevity #AnimalHealth #PetWellness #DrugDevelopment #ClinicalTrials #AgingResearch #LifeSciences #InvestorNews

MP Evans Group PLC (AIM:MPE) chief executive Matthew Coulson talked with Proactive's Stephen Gunnion about the company’s strong half-year results, highlighting a 50% jump in operating profit. Coulson attributed the performance to two main drivers: improved crop mix and firm palm oil prices. “We changed the mix of crop going through our mills,” he said, noting that more of the company’s own crop—known for its superior quality and lower production cost—was processed during the period. Coulson explained that this strategy improved both margins and efficiency, enabling MP Evans to extract more oil at a lower cost base. He also pointed to a 10% increase in certified sustainable palm oil output, which supports customer demand and adds a premium to product pricing. Turning to shareholder value, Coulson highlighted a 20% increase in the interim dividend and reiterated the company’s commitment to maintaining or growing shareholder returns, a track record that has continued for 35 years. He added that MP Evans maintains a strong net cash position, allowing for reinvestment, including a recent acquisition of 3,000 hectares in East Kalimantan to support future expansion. Coulson concluded by stating that trading into the second half of the year remains strong with continued firm pricing. Watch more interviews on Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #PalmOil #MPEvans #SustainableAgriculture #Agribusiness #DividendStocks #CertifiedPalmOil #EastKalimantan #CropYield #H1Results #ProactiveInvestors

Itaconix PLC (AIM:ITX, OTCQB:ITXXF) CEO John Shaw takes Proactive's Stephen Gunnion through the company’s latest financial results and operational progress as it continues its push towards profitability and scale. Shaw said, “We’re going to be a large specialty ingredient company. 20 million, 40 million, 100 million. Those are our ambitions,” highlighting confidence in the company’s growth prospects through scale inhibitors and odour neutralisers used in high-performing detergents. He outlined progress against four key goals for 2025, including rebuilding the North American cleaning customer base, expanding in Europe, increasing adoption of odour neutralisers, and launching its biomaterials platform. Shaw confirmed the company has already achieved these, with its SPARX programme set to deliver 10 new products to market by year-end. He also referenced recent momentum in Europe, new commercial traction through a partnership with Croda, and early demand via e-commerce for its BIOAsterix offering. On capacity, Shaw said the company is positioned to meet forecast demand through 2026 and is already preparing for 2027, noting that longer-term plans may include new facilities to support larger customer volumes. Shaw expressed confidence in ending 2025 strongly and expects continued growth into 2026. For more updates from Itaconix and other innovative companies, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications so you never miss an update. #Itaconix #SpecialtyIngredients #OdourNeutralisers #PlantBasedChemicals #SustainableIngredients #DetergentInnovation #JohnShaw #CleanTech #Croda #InvestorUpdate #SPARXProgramme #BIOAsterix #ProfitabilityPath #GreenChemistry #ProactiveInvestors

ATOME PLC (AIM:ATOM) CEO Olivier Mussat talked with Proactive's Stephen Gunnion about the company’s landmark offtake agreement for its Villeta Project in Paraguay. The project is described by Mussat as the first industrial-scale, fully dedicated green fertiliser facility. Powered by renewable energy, it will convert green hydrogen into ammonia and ultimately produce 260,000 tons per year of calcium ammonium nitrate fertiliser. Mussat explained, “Offtake means who is going to buy your product, at what price, and for how long? Because that determines the bankability of your project.” He confirmed that ATOME has signed a ten-year take-or-pay agreement with Yara, one of the world’s largest fertiliser companies, covering 100% of production, with an option to renew. He highlighted that Yara sells over 6 million tons of fertiliser annually in Latin America, making it a significant long-term partner. The CEO emphasised that this partnership ensures guaranteed revenues before construction even begins, which is a critical factor in securing financing. He noted that ATOME has already purchased land, completed environmental and social impact assessments, and agreed on EPC terms with Casale. The next steps will focus on finalising financing with equity led by Hy24 and debt discussions involving institutions such as IDB, FMO, the European Investment Bank, and IFC. Visit Proactive’s YouTube channel for more company interviews and updates. Don’t forget to like this video, subscribe, and enable notifications so you never miss future content. #ATOME #GreenFertilizer #VilletaProject #Yara #RenewableEnergy #GreenHydrogen #Ammonia #SustainableAgriculture #ProjectFinance #ProactiveInvestors

Active Energy Group PLC (AIM:AEG, OTCQB:ATGVF) treasury advisor Adrian Rowles talked with Proactive's Stephen Gunnion about the company’s newly outlined digital treasury strategy and its role in supporting renewable energy operations. Rowles explained that the approach is “compliance-led and diversified, building resilience and scaling carefully,” with a clear 12 to 24-month roadmap. In the first year, the focus will be on structure and transparency, while by the second year, digital assets are expected to deliver a meaningful contribution to operational income. A portion of the company’s recent £2.50 million capital raise has been earmarked for treasury management, with around 30% of working capital to be placed into digital assets. Rowles noted that reserves will be primarily held in Bitcoin and Ethereum, but there are also plans to explore alternative opportunities, such as hedging strategies to better manage crypto cycles and generate a predictable yield. He emphasised that success will be measured through safety, liquidity, and risk-adjusted returns. Assets will be held with regulated partners, diversification caps will limit exposure to any single asset, and safeguards will be tested to ensure cautious but efficient management. Rowles highlighted that the integration of digital assets with renewables is designed to create sustainable income streams that strengthen the group’s core operations. For more updates from Proactive, visit our YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications so you never miss future content. #ActiveEnergyGroup #DigitalTreasury #CryptoStrategy #Bitcoin #Ethereum #RenewableEnergy #TreasuryManagement #DigitalAssets #SustainableFinance #CryptoTreasury

International Lithium Corp. (TSX-V:ILC, OTCQB:ILHMF) chairman and CEO John Wisbey talked with Proactive's Stephen Gunnion about the company’s latest strategic developments, including its option to acquire Lepidico’s interest in the Karibib Lithium, Rubidium and Cesium project in Namibia. Wisbey explained that the Karibib project brings both scale and advanced development, with a feasibility study already completed in 2020. He highlighted that the resource contains significant lithium, a substantial rubidium component, and enough cesium to meet a year of global demand. “Our research shows, that was validated by some external research, shows that it's the largest declared rubidium resource in Africa,” he noted. He described the project as complementary to International Lithium’s Raleigh Lake project in Canada, which has already reached the PEA stage and also contains both lithium and rubidium. Namibia’s proximity to Zimbabwe, where the company has pending applications, was also seen as a geographic advantage. If the option is exercised, Wisbey said the immediate focus will be on due diligence, establishing a drilling program to expand resources, and aligning reporting with Canadian NI 43-101 standards. He added that financing will be supported by proceeds from past asset sales, with further planning under discussion with investors. The company emphasized that there is a possibility that the option may not be exercised, especially if Lepidico Namibia encounters an adverse outcome in an arbitration dispute with the Chinese company Jiangxi Jinhui Lithium Co. Ltd., which involves claims and counterclaims. This arbitration in Singapore is expected to conclude in September or October 2025. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications for future content. #Lithium #Rubidium #CriticalMetals #InternationalLithium #Mining #Namibia #BatteryMetals #EnergyTransition #RaleighLake #ProactiveInvestors

Tonix Pharmaceuticals Holdings CEO Dr Seth Lederman joined Steve Darling from Proactive to share that the company presented four scientific posters at the PAINWEEK 2025 conference in Las Vegas, Nevada, showcasing robust data from two pivotal Phase 3 trials of Tonmya® for the treatment of fibromyalgia. The first study, RELIEF, was a 14-week randomized, double-blind, placebo-controlled trial, while the second, RESILIENT, served as a confirmatory efficacy and safety trial. Results across both studies demonstrated that Tonmya significantly reduced fibromyalgia-related pain while maintaining a favorable tolerability profile. Unlike conventional pain therapies, Tonmya is designed to pharmacologically target nonrestorative sleep by antagonizing receptors that regulate sleep architecture—addressing a central mechanism thought to perpetuate fibromyalgia symptoms. Dr. Lederman noted that beyond reducing pain, Tonmya’s mechanism of action may help improve a wide spectrum of fibromyalgia symptoms, potentially supporting earlier diagnosis, timely intervention, and improved long-term outcomes. Importantly, the therapy represents a non-opioid treatment option at a time when safer alternatives are in high demand. With FDA approval secured, Tonix is now preparing to launch Tonmya commercially in the coming quarter, marking a transformative milestone for both the company and the fibromyalgia community. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #TonixPharmaceuticals #Tonmya #Fibromyalgia #FDAApproval #NonOpioid #PainManagement #ChronicPain #NociplasticPain #Cyclobenzaprine #MoveFibroForward #Painweek2025

Arrow Exploration CEO Marshall Abbott joined Steve Darling from Proactive to provide a comprehensive operational update on the company’s rapidly advancing activities in Colombia. Abbott revealed that Arrow has successfully made three new oil discoveries in the region—discoveries that have already led to the drilling of 39 development wells. He described this as evidence of the project’s “scope and repeatability,” underscoring the company’s ability to consistently replicate exploration success and swiftly convert it into production. Abbott noted that Arrow has emerged as one of the most active and dynamic operators in Colombia’s oil sector. The company is currently producing approximately 4,800 barrels of oil per day, representing a 45% increase compared to the same period last year. This surge in production highlights the effectiveness of Arrow’s drilling program and its ability to rapidly scale output from newly discovered resources. Looking ahead, Abbott said the company will continue to pursue a strategy focused on low-risk exploration drilling to drive further growth. One exploration well is scheduled to spud on September 16, with three additional wells planned to follow shortly thereafter. He emphasized that this steady pipeline of drilling activity is designed to unlock new reserves while maintaining predictable operational performance. Abbott also discussed the company’s investments in critical water disposal infrastructure—a key component in supporting sustained production growth. “Now we have the capacity to handle just under 140,000 barrels of water per day with three disposal wells,” he explained. This expanded capacity allows Arrow to increase pump speeds across its producing wells, which in turn supports higher production rates and operational efficiency. Financially, Arrow remains in a robust position. The company is currently debt free and holds approximately $13 million in cash, with strong monthly cash flow supporting both ongoing operations and growth initiatives. Abbott confirmed that Arrow has set an internal target of reaching 10,000 barrels per day, a goal the company plans to achieve through a combination of organic growth from its existing portfolio and strategic asset acquisitions that complement its core operations in Colombia. #proactiveinvestors #arrowexplorationinc #aim #axl #tsxv #axl #ColombiaEnergy #MarshallAbbott #Q1Results #OilDrilling #EnergyInvestment #SeismicSurvey #WaterDisposal #PrepaymentDeal #ExplorationAndProduction #LlanosBasin #EnergySector #ProactiveInvestors